RxGen is a specialty translational research company devoted to understanding and overcoming human disease through innovative preclinical modeling. We apply significant preclinical and therapeutic domain expertise in ophthalmic, central nervous system, cardiovascular and metabolic disease to develop and apply translational models to meet the scientific needs of the global biomedical research community.
Our MD and/or PhD trained study directors and highly trained technical team engage with leading academic research institutions, venture-backed start-ups, and biotechnology and pharmaceutical companies to advance a diversity of therapeutic discovery and development programs. RxGen’s research facilities are AAALAC accredited and GLP compliant, providing a wide range of preclinical research expertise, from preclinical strategy to disease model validation to IND-enabling study design and execution.
To develop, validate, and apply the most predictive preclinical models to accelerate candidate evaluation, selection and development, and reduce the risks and costs of clinical failure for therapeutic discovery and development organizations around the world.
To be a leading provider of predictive preclinical models and technologies that drive significant gains in research and development productivity across the biomedical research community.